Shared Savings Legislation Could Increase Medicare Biosimilar Access
Proposed Three-Year Project Would Assess Benefit Of Additional Payments
Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.
You may also be interested in...
AAM Sees Boon From Biden Order And CMS Biosimilar Action
The US Association for Accessible Medicines has welcomed an executive order from president Joe Biden aimed at lowering prescription drug costs, shortly after the AAM’s Biosimilars Council praised payment changes for biosimilars made by the Centers for Medicare & Medicaid Services.
Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’
The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.
Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General
If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand, the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.